These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27893585)

  • 1. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
    Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
    Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
    JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
    El Zaoui I; Bucher M; Rimoldi D; Nicolas M; Kaya G; Pescini Gobert R; Bedoni N; Schalenbourg A; Sakina E; Zografos L; Leyvraz S; Riggi N; Rivolta C; Moulin AP
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2764-2772. PubMed ID: 31247083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
    Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
    Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response for 36 months after BRAF and MEK inhibitor therapy for locally advanced gallbladder melanoma.
    Hakim S; Orosey M; Edhi A; Amin M; Cappell MS
    Minerva Gastroenterol Dietol; 2019 Sep; 65(3):243-246. PubMed ID: 31115206
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors.
    Mizukami Y; Kanemaru H; Nakamura K; Hashigo S; Kajihara I; Miyashita A; Aoi J; Fukushima S; Honda Y; Ihn H
    J Dermatol; 2020 Apr; 47(4):e126-e127. PubMed ID: 31872454
    [No Abstract]   [Full Text] [Related]  

  • 11. The future of melanoma therapy: developing new drugs and improving the use of old ones.
    Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
    Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to BRAF-targeted therapy in melanoma.
    Sullivan RJ; Flaherty KT
    Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
    Cagney DN; Alexander BM; Hodi FS; Buchbinder EI; Ott PA; Aizer AA
    J Neurooncol; 2016 Sep; 129(3):389-393. PubMed ID: 27401151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
    Nti AA; Serrano LW; Sandhu HS; Uyhazi KE; Edelstein ID; Zhou EJ; Bowman S; Song D; Gangadhar TC; Schuchter LM; Mitnick S; Huang A; Nichols CW; Amaravadi RK; Kim BJ; Aleman TS
    Retina; 2019 Mar; 39(3):502-513. PubMed ID: 29324592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting
    Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
    Roque A; Odia Y
    CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
    Carlino MS; Gowrishankar K; Saunders CA; Pupo GM; Snoyman S; Zhang XD; Saw R; Becker TM; Kefford RF; Long GV; Rizos H
    Mol Cancer Ther; 2013 Jul; 12(7):1332-42. PubMed ID: 23645591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
    Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
    J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
    Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.